Scotland strikes CF drug deal with Vertex, rest of UK still waitingPatients in Scotland will gain access to Vertex’s cystic fibrosis drugs Orkambi and Symkevi, after the company signed Share XScotland strikes CF drug deal with Vertex, rest of UK still waitinghttps://pharmaphorum.com/news/scotland-strikes-cf-drug-deal-with-vertex-rest-of-uk-still-waiting/
Pharma stocks fall after Pelosi’s plan to cut drug prices emerges on Capitol HillPharma stocks fell yesterday after an early draft of House Speaker Nancy Pelosi’s plan to reduce drug prices Share XPharma stocks fall after Pelosi’s plan to cut drug prices emerges on Capitol Hillhttps://pharmaphorum.com/news/pharma-stocks-fall-after-pelosis-plan-to-cut-prices-emerges-on-capitol-hill/
Xeris’ severe low blood sugar pen gets FDA approvalAfter 14 years of operations Xeris Pharma has its first-ever product approval, claiming an FDA okay for a Share XXeris’ severe low blood sugar pen gets FDA approvalhttps://pharmaphorum.com/news/xeris-severe-low-blood-sugar-pen-gets-fda-approval/
Novartis’ Kymriah okayed for funding in Scotland for lymphomaNovartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness Share XNovartis’ Kymriah okayed for funding in Scotland for lymphomahttps://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/
The Japanese healthcare revolutionSomething that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and Share XThe Japanese healthcare revolutionhttps://pharmaphorum.com/views-analysis-oncology/the-japanese-healthcare-revolution/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
NHS funds eye gene therapy, after Novartis cuts £613,000 priceNICE has recommended the NHS should fund Novartis’ Luxturna for a rare eye disorder, after the company agreed Share XNHS funds eye gene therapy, after Novartis cuts £613,000 pricehttps://pharmaphorum.com/news/nhs-funds-eye-gene-therapy-after-novartis-cuts-613000-price/
Mylan’s Lantus biosimilar held up by manufacturing issueMylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient Share XMylan’s Lantus biosimilar held up by manufacturing issuehttps://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/
Novartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarNovartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar Share XNovartis strikes marketing deal for Polpharma’s potential Tysabri biosimilarhttps://pharmaphorum.com/news/novartis-strikes-marketing-deal-for-polpharmas-potential-tysabri-biosimilar/
